Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:56 AM
Ignite Modification Date:
2025-12-26 @ 10:56 AM
NCT ID:
NCT00830908
Eligibility Criteria:
Inclusion Criteria:
* Diagnosis of seborrheic dermatitis of the scalp
* PGA of 2 (mild) or greater at baseline
* TDSS score at baseline of 2 or greater, for both scaling and inflammation
* Must agree to use of non-medicated shampoos during study period; must refrain from use of other medicated scalp products during the trial
Exclusion Criteria:
* Use of any topical or oral products that would affect assessment of the scalp SD condition, in the opinion of the primary investigator, within the following periods prior to baseline:
* Medicated shampoos within 2 weeks of baseline
* Topical scalp medications within 2 weeks of baseline
* Oral medications affecting the scalp within 4 weeks of baseline
* Other medications determined by the investigator to potentially affect the assessment of SD = washout to be determined by the investigator, as appropriate to the known medication properties
* Any current or past medical condition, including active dermatitis or any other dermatological condition, which might interfere with assessment of dandruff
* Patients using any medications that may increase photosensitivity, and thus pose a risk when undergoing LaserComb therapy
* Patients with known adverse reactions, allergy or hypersensitivity to laser light components/light sensitivity conditions
* Patients who have received any investigational drug within 30 days prior to study entry.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
50 Years
Study:
NCT00830908
Study Brief:
Protocol Section:
NCT00830908